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ABSTRACT
Background: Atherosclerosis is an inflammatory disease of the blood vessel wall, characterized in early 
stages by endothelial dysfunction, recruitment and activation of monocyte/macrophages. Glimepiride is one 
of the third generation sulphonylurea drugs, useful for control of diabetes mellitus type two and it may exert 
anti inflammatory activity, by induction of nitric oxide production or through selective suppression of the 
cyclooxygenase pathway. Repaglinide is a new hypoglycemic agent, and a member of the carbamoylmethyl 
benzoic acid family. Some results from the literature demonstrate that repaglinide has favorable effects on 
the parameters of antioxidative balance. Objectives: The objective of the present study was to assess the 
effect of glimepiride and repaglinide on atherosclerosis via interfering with the inflammatory and oxidative 
pathways. Materials and Methods: Twenty four local domestic male rabbits were involved in this study. 
The animals were randomly divided into four groups; Group I rabbits fed normal chow (oxiod) diet for 10 
weeks. Group II rabbits were fed with 1% cholesterol enriched diet. Group III rabbits were fed with 1% 
cholesterol enriched diet together with Glimepiride (0.1 mg/kg once daily before morning feed). Group 
IV rabbits were fed with 1% cholesterol enriched diet together with Repaglinide (0.3 mg/kg once daily 
before morning feed). Blood samples were collected before (0 time) and every two weeks of experimental 
diets for measurement of serum triglycerides (TG), total cholesterol (TC), High-density lipoprotein 
cholesterol (HDL-C), high sensitive C - reactive protein (hsCRP), Interleukin – 6 (IL-6) and Tumor Necrosis 
Factor alpha (TNF-α) levels. At the end of 10 weeks, the aorta was removed for measurement of aortic 
Malondialdehyde (MDA), reduced glutathione (GSH) and aortic intimal thickness. Results: Glimepiride 
and repaglinide treatment did show significant effect on lipid parameters compared with induced untreated 
group (P < 0.05). Also, they significantly reduced the elevation in hsCRP, IL-6, TNF-α, aortic MDA and 
aortic intimal thickness compared with induced untreated group (P < 0.05), and they helped to restore 
the aortic GSH levels (P < 0.05). Conclusions: Glimepiride and repaglinide may reduce atherosclerosis 
progression in hypercholesterolemic rabbits by interfering with the inflammatory and oxidative pathways 
without affecting lipid parameters.
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INTRODUCTION
A main consequence of type II diabetes is accelerated onset 
of atherosclerosis, which is an important risk factor in the 
progression of ischemic cardiovascular disease. Successful 
management of hyperglycemia alone is usually inadequate 
to prevent cardiovascular events, as many other recognized 
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risk factors such as hyperlipidimia, hypertension, and obesity 
are often present concurrently in the diabetic population.[1] 
Also the incidence of atherosclerosis is 3 – 4 times greater 
in diabetics than non-diabetics at comparable plasma total 
cholesterol concentrations.[2] Accordingly, prevention of 
onset and progression of atherosclerosis, as well as tight 
glycemic control are essential goals of treatment in type 
two diabetic patients. It has been extensively demonstrated 
that inflammation plays a central role in atherogenesis, and 
mediates all stages of this disease, from initiation through 
progression and, ultimately, the thrombotic complications 
of  atherosclerosis.[3]
Inflammation contributes to the formation and progression 
of atherosclerosis, and the therapeutic potential of some 
anti-inflammatory drugs has been evaluated for possible 
anti atherosclerotic activity. Recent findings suggest that 
some agents with anti-inflammatory properties appear to 
have beneficial effects on atherosclerosis, or subsequent 
risk for cardiovascular events.[4] Sulfonylureas have been 
widely used in the recent years as a first-line treatment 
in type two diabetic patients in whom the blood glucose 
levels could not be effectively controlled by diet al.one. 
Glimepiride (Amaryl®), a third-generation sulfonylurea 
administered once daily, has been established to offer 
therapeutic advantages over other sulfonylureas in terms 
of glucose level-dependent insulinotropic action, insulin-
sparing effects, and hypoglycemic risk.[5-7] Furthermore, 
glimepiride exhibits inhibitory effects on human platelets 
aggregation through selective suppression of the 
cyclooxygenase pathway, suggesting that it may have 
therapeutic potential in diabetic patients with enhanced 
platelet function.[8] In addition, there are several reports 
showing beneficial effects of sulfonylureas against the 
development of cardiovascular disease in rabbits fed an 
atherogenic diet,[9] as well as in hyperglycemic patients.[10] 
Recently, glimepiride has been demonstrated to inhibit the 
development of atheromatous plaques in the thoracic aorta 
of high-cholesterol fed rabbits.The mechanism by which 
glimepiride induces atheroprotective effects remains to be 
elucidated.[11]
Repaglinide is a new hypoglycemic agent, and a 
member of the carbamoylmethyl benzoic acid family. 
Its mechanism of action is partially similar to that of 
sulfonylurea. It stimulates the release of insulin from 
pancreatic beta-cells by inhibition of potassium efflux 
lead to closure of Adenosine triphosphate (ATP) 
regulated Potassium Ino (K+) channels.[12] This results 
in depolarization of the cell and subsequent opening 
of the calcium channels, leading to an influx of calcium 
into the cells, and causing release of insulin.[13] However, 
repaglinide regulates these channels via a different 
binding site than sulfonylurea. Repaglinide improves 
glycemic control through a physiological action on the 
reduced phase of insulin secretion in type 2 diabetes 
mellitus.[14] Some results from the literature demonstrate 
that repaglinide has a favorable effect on the parameters 
of antioxidative balance. It significantly improved the 
activity of superoxide dismutase and diminished lipid 
peroxidation in the serum of type 2 diabetic patients.[15] 
It is possible that the drug itself, being a benzoic acid 
derivative, has some antioxidant activity.[15]
MATERIALS AND METHODS
Twenty four local domestic male rabbits were involved in 
this study. The animals were randomly divided in to four 
groups; Group I rabbits fed normal chow (oxiod) diet 
for 10 weeks. Group II rabbits fed with 1% cholesterol 
enriched diet for 10 weeks. Group III rabbits fed with 
1% cholesterol enriched diet together with glimepiride 
(0.1 mg/kg once daily before morning feed for 10 
week).[16] The drug was prepared immediately before use as 
a suspension in 5% starch. Group IV rabbits were fed with 
1% cholesterol enriched diet together with repaglinide (0.3 
mg/kg once daily before morning feed for 10 week).[17] The 
drug was prepared immediately before use as a suspension 
in 5% starch. The blood samples were collected before 
(0 time) and every two weeks on experimental diets for 
measurement of serum triglycerides (TG), total cholesterol 
(TC), HDL-C, high sensitive C - reactive protein (hsCRP), 
IL-6 and TNF-α level. At the end of 10 weeks, the aorta 
was removed for measurement of aortic Malondialdehyde 
(MDA), reduced glutathione (GSH) and aortic intimal 
thickness.
RESULTS
There was a slight insignificant increase in the body 
weight of Glimepiride and Repaglinide receiving groups 
suggesting that food consumption probably was similar in 
all the groups and cholesterol or glimepiride or repaglinide 
had no effect on body weight. Also no significant 
changes were observed in the glucose concentration of 
the glimepiride and repaglinide receiving groups during 
the period of experiment. A significant increase was 
onserved in the blood glucose concentration levels of 
the induced untreated group, and this may be because an 
atherogenic diet reduces plasma insulin levels and enhances 
gluconeogenesis as shown in Table 1.
Compared with the control, levels of TC, TG, HDL-C, 
LDL-C, VLDL-C, atherogenic index, hsCRP, IL-7 Journal of Cardiovascular Disease Research Vol. 3 / No 1
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6, TNF-α, MDA and aortic intimal thickness were 
increased, and GSH were decreased in the animals on the 
atherogenic diet (P<0.05). Glimepiride and repaglinide 
treatment did not show any significant effect on the lipid 
parameters when compared with the induced untreated 
group (P>0.05). Glimepiride and repaglinide significantly 
reduced the elevation in hsCRP, IL-6, TNF-α, aortic 
MDA and aortic intimal thickness compared with 
induced untreated group (P<0.05). Also they restore 
aortic GSH level (P<0.05) as shown in Tables 2-5 and 
Figures 1-9.
DISCUSSION
Accelerated atherosclerosis accompanied by high risk of 
premature mortality from cardiovascular disease (eg coronary 
heart disease) is a frequent and serious complication of type 
two diabetes.[18] Thus prevention of onset or progression 
of atherosclerosis, as well as adequate glycemic control is 
mandatory for the treatment of patients with this entity. 
The present study was conducted to assess the effect of 
glimepiride and repaglinide on atherosclerosis via interfering 
with the inflammatory and oxidative pathways.
Effects of glimepiride on study parameters
In this study we demonstrated that treatment with 
glimepiride appeared to have no significant effect on lipid 
parameters in comparison with the induced untreated 
group, and this may be due to the fact that change in lipid 
parameter induced by high fat diet overrides any changes 
expected from glimepiride. Moreover, in the present study 
glimepiride treatment significantly reduced the elevation 
of inflammatory markers (hs-CRP, IL-6 and TNF-α) in 
atherosclerosis model of hypercholesterolemic rabbit, 
suggesting that glimepiride inhibited vascular inflammation 
induced by high cholesterol diet. Glimepiride has been 
reported to show extra pancreatic actions including 
phosphorylation of insulin receptor substrate-1, which is 
Table 1: Changes of body weight (kg) and blood sugar 
(mg/dl) levels of the four experimental groups of 
rabbits. The data was expressed as Mean ± Standard 
error of mean (SEM) (N = 6 in each group) using paired 
T-test
Body weight  
(Kg)
Blood sugar  
(mg/dl)
Normal control Zero time 1.5 ± 0.1 110 ± 4.2
10 weeks 1.5 ± 0.09 100 ± 6.2
Induced untreated Zero time 1.55 ± 0.1 110 ± 6
10 weeks 1.3 ± 0.05 134 ± 4*
Glimepiride 0.1 mg/kg Zero time 1.52 ± 0.1 112 ± 5.2
10 weeks 1.64 ± 0.05 124 ± 5.7
Repaglinide 0.3 mg/kg Zero time 1.6 ± 0.07 107 ± 5.3
10 weeks 1.73 ± 0.06 120 ± 6.8
*P< 0.05
Table 2: Changes of body weight and rabbit’s serum lipid profile [total cholesterol (TC), triglyceride (TG), low 
density lipoprotein (LDL) and high density lipoprotein (HDL)] in the four experimental groups. The data was 
expressed as Mean ± Standard Error of mean (SEM) (N = 6 in each group) using paired T-test
Body weight 
(kg)
LDL (mg/dl) TC (mg/dl) TG (mg/dl) HDL (mg/dl)
Normal control Zero time 1.5 ± 0.2 63 ± 1.6 85 ± 2.92 43.3 ± 1.71 15.6 ± 1.28
10 weeks 1.5 ± 0.9 68 ± 2.3 88 ± 3.26 45 ± 3.5 16.5 ± 1.4
Induced untreated Zero time 1.6 ± 0.1 73 ± 1.9 90 ± 1.65 44 ± 2.87 16.2 ± 1.29
10 weeks 1.4 ± 0.06 719 ± 14.62 994 ± 28* 324 ± 20.5* 37 ± 1.74*
Glimepiride 0.1 mg/kg Zero time 1.54 ± 0.3 74 ± 3.57 91 ± 3.36 42 ± 2.17 16.4 ± 1.37
10 weeks 1.67 ± 0.04 711 ± 22.75 977 ± 9.9 319 ± 9.2* 42.5 ± 3.08*
Repaglinide 0.3 mg/kg Zero time 1.62 ± 0.03 66 ± 1.84 89 ± 4. 4 40 ± 2.89 15.7 ± 1.36
10 weeks 1.68 ± 0.04 675 ± 14.58 957 ± 11.72* 320 ± 9.7* 40.6 ± 2.99*
*P<0.05, Where, TC = total cholesterol; TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein (HDL).
Table 3: Changes of rabbits serum inflammatory markers [high sensitive C - reactive protein (hs-CRP),  
Interleukin – 6 (IL-6) and Tumor Necrosis factor (TNF- α)] of the four experimental groups. The data was  
expressed as Mean ± Standard Error of mean (SEM) (N = 6 in each group) using paired T-test
hs-CRP (mg/l) IL-6 (pg/ml) TNF-α (pg/ml)
Normal control  Zero time 3.5 ± 0.5 0.75 ± 0.1 0.6 ± 0.09
10 weeks 4.3 ± 0.7 1.1 ± 0.09 1.05 ± 0.06
Induced untreated Zero time 4.2 ± 0.9 1.06 ± 0.05 0.77 ± 0.1
10 weeks 20.7 ± 1.7* 5.5 ± 0.5* 7.05 ± 0.44*
Glimepiride 0.1 mg/kg Zero time 3.8 ± 0.3 1.1 ± 0.09 0.9 ± 0.1
10 weeks 7.4 ± 1.1* 2.4 ± 0.2* 2.5 ± 0.2*
Repaglinide 0.3 mg/kg Zero time 4.1 ± 0.5 0.9 ± 0.08 0.85 ± 0.05
10 weeks 10.4 ± 0.6* 2.8 ± 0.3* 2.7 ± 0.17*
*P<0.05, Where, hs-CRP = high sensitive C - reactive protein; IL – 6 = Interleukin – 6; TNF- α = Tumor Necrosis factor.8 Journal of Cardiovascular Disease Research Vol. 3 / No 1
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a regulator of phosphaoltidylinosit 3-kinase (PI3-kinase) in 
adipocytes.[19] PI3-kinase has been shown to be involved in 
agonist-induced nitric oxide (NO) production in vascular 
endothelial cells.[20] Collectively, these findings suggest that 
glimepiride may stimulate NO production in endothelial 
cells through a PI3-kinase dependent pathway. Kenyon   
et al. have shown that the production of NO might be 
needed as a defensive factor in various models of acute or 
chronic inflammation.[21]
In addition to that, it was seen that glimepiride had 
significantly reduced aortic MDA levels suggesting a 
decrease in reactive oxygen species levels and subsequent 
lipid peroxidation. Also Glimepiride had significant effect 
on the aortic GSH levels, and prevented GSH depletion in 
hypercholesterolemic rabbit, and thus, helped to maintain 
an antioxidant balance which is important for vascular 
protection against lipid peroxide. There are two possible 
explanations for antioxidant capacity of glimepiride, firstly 
through inhibition of cellular cyclooxygenase pathways,[8] 
and the second possible mechanism may be related to 
the fact that glimepiride has the property to up-regulate 
antioxidant enzyme genes like paraoxonase, superoxide 
dismutase and catalase gene through reducing the activation 
of the redox sensitive nuclear factor kappa-B (NF-be),or 
through that glimepiride possessed agonistic activities for 
PPARγ.[22-24]
Also, glimepiride treatment significantly reduced aortic 
intima thickness in rabbits compared with the induced 
untreated group of rabbits. Atherosclerosis is now 
widely accepted as a chronic inflammatory process. Low-
grade inflammation, enhanced oxidant stress and lipid 
peroxidation may predispose an individual to developing 
atherosclerosis. The athero-protective effect of glimepiride 
is due to interference with the inflammatory and oxidative 
pathways in hypercholesterolemic rabbits. In addition to 
that, glimepiride also specifically inhibits some processes 
in the early cellular events of atherosclerosis, which may 
include: Adherence of circulating blood monocytes to 
vascular endothelial cells; migration of adherent monocytes 
into the sub endothelial space and their subsequent 
differentiation into macrophages; oxidative alteration of 
LDL mediated by vascular endothelial cells, smooth muscle 
cells, or macrophages; and, uptake of oxidative LDL   
by macrophages by scavenger receptors to generate foam 
cells.[25] Glimepiride has a inhibitory effect on cell-mediated 
LDL oxidation, and it may prevent the oxidation processes, 
and also reduce aortic intimal thickness while inhibiting the 
progression of atherosclerotic lesion.
Effects of repaglinide on study parameters
In the present study we found that repaglinide had no 
significant effects on lipid profile in comparison with the 
induced untreated group. This finding may be due to that 
the high cholesterol diet may mask any changes in the 
lipid parameter. Repaglinide is a new oral anti diabetic 
agent with a possible antioxidant activity. Therefore, in 
the present study we tested if repaglinide has a potential 
anti-inflammatory effect beyond its antioxidative activity, 
and if it has potential capability of controlling the 
initiation and progression of atherosclerotic lesions. 
The result of our study demonstrated a significant effect 
of repaglinide on inflammatory markers (hsCRP, IL-6 
andTNF-α) in rabbits on a high fat diet, suggesting a 
possible anti-inflammatory activity of repaglinide on the 
vascular inflammatory responses induced by high fat diet. 
The possible explanation of anti-inflammatory effect of 
repaglinide could be related to it is antioxidative activity.
Antioxidant agents might be practical therapeutic tools 
which interfere with the production of pro-inflammatory 
and cytotoxic mediators.[26] Esposito et al. showed that 
during glucose infusion, the rise in plasma cytokines 
induced by hyperglycemia was completely prevented by 
the antioxidant agent glutathione.[27]
Moreover, repaglinide significantly inhibited the increase 
of aortic MDA induced in high cholesterol-fed rabbits 
suggesting a decrease in reactive oxygen species and 
subsequent lipid peroxidation. Also, Repaglinide 
Table 5: The means of rabbit’s aortic intima thickness 
of the four experimental groups at the end of 
experiment have been given below. The data was 
expressed as Mean ± Standard error of mean (SEM)  
(N = 6 in each group) using paired T-test
Group Aortic intima thickness (µm)
Normal control 32.4 ± 2.7
Induced untreated 334.82 ± 53.5*
Glimepiride 0.1 mg/kg 203.03 ± 22.35*
Repaglinide 0.3 mg/kg 195.6 ± 23.1*
*P<0.05
Table 4: The means’ of rabbits’ aortic Oxidative stress 
parameters [Malondialdehyde (MDA) and Glutathione 
(GTH) and reduced glutathione (GTH)] in the four 
experimental groups at the end of experiment have 
been given below. The data was expressed as Mean 
± Standard error of mean (SEM) [N=6 in each group] 
using paired T-test




Normal control 1.4 ± O.14 38.3± 2.46
Induced untreated 7.3 ± O.55* 21.7± 1.75*
Glimepiride 0.1 mg/kg 3.6 ± O.44 30.4 ± 2.2
Repaglinide 0.3 mg/kg 2.35 ± 0.26 34.5 ± 1.8
*P < 0.05, Where, MDA = Malondialdehyde; GTH = glutathione.9 Journal of Cardiovascular Disease Research Vol. 3 / No 1
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significantly increased aortic GTH level, and thus it 
prevented GSH depletion in hypercholesterolemic rabbits, 
and thus, maintained an antioxidant reserve which is crucial 
for vascular protection against lipid peroxide. Repaglinide 
is a benzoic acid derivative that lacks a sulfa group, hence 
the possible explanation of the antioxidant activity of 
repaglinide is due to its benzoic acid group.[28] Also, studies 
have demonstrated that benzoic acid derivatives could also 
have an antioxidant activity.[29]
The present study demonstrated that repaglinide treatment 
significantly suppresses the increase in intimal thickness 
Figure 1: Effect of glimepiride 0.1 mg/kg /day and repaglinide 0.3 mg/
kg /day treatment on serum total cholesterol (TC)  levels (mg/dl) during 
the experimental treatment
Figure 2: Effect of glimepiride 0.1 mg/kg /day and repaglinide 0.3 mg/
kg /day treatment on serum high sensitive C - reactive protein (hs-CRP)   
(mg/l) and serum Interleukin – 6 (IL-6) (pg/ml) in comparisons to the 
two control group (normal and induced untreated) 
Figure 3: Effect of glimepiride 0.1 mg/kg /day and repaglinide 0.3 mg/kg 
/day treatment on serum tumor necrosis factor alpha (TNF-α)  (pg/ml) in 
comparisons to the two control group (normal and induced untreated)
Figure 4: Effect of glimepiride 0.1 mg/kg /day and repaglinide 0.3 mg/
kg /day treatment on aortic malondialdehyde (MDA)  µmole/gm aorta 
and aortic glutathione (GTH) nmole/mg aorta in comparisons to the 
two control group (normal and induced untreated)
Figure 5: Effect of glimepiride 0.1 mg/kg /day and repaglinide 0.3 mg/
kg /day treatment on aortic intimal thickness level (µm) at the end of 
experiment
Figure 6: Photomicrograph of histomorphometric section in aortic 
arch of rabbits fed on normal diet for 10 weeks (normal control) show 
appearance of arterial wall layers: Lumen (L). Intact continuous 
endothelium, Intima (I), regularly arranged smooth muscle fibers, 
media (M) and adventitia (A). The section stained with hematoxylin 
and eosin (×10)10 Journal of Cardiovascular Disease Research Vol. 3 / No 1
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induced by atherogenic diet in rabbits as compared with 
induced untreated group. In our study we found that 
Repaglinide treatment exerts an anti inflammatory effect 
by reducing levels of hsCRP, IL-6 andTNF-α and also an 
antioxidant effect by reducing lipid peroxide (MDA) levels 
and enhancing GTH. Thus, these findings may provide 
mechanistic answers as to how can repaglinide reduce 
aortic intima thickness via a number of pathways, including 
the suppression of systemic inflammatory response and 
oxidative stress.
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